Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma

doi:10.3748/wjg.v30.i17.2321

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 30, Issue 17

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (2198)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-3) series.

Item

Count

PDF

HTML

1095

Figures (1-2)

161

Tables (1-3)

152

Sum=1444

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

175

Download

208

Sum=383

Publishing Process of This Article

Item

Count

Browse

Download

205

Sum=287

May 7, 2024 (publication date) through Nov 7, 2024

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastroenterol. May 7, 2024; 30(17): 2321-2331
Published online May 7, 2024. doi: 10.3748/wjg.v30.i17.2321

Full Size Figure Download Figure

Figure 1 Prognostic outcomes of patients with hepatocellular carcinoma followed up within 25 months after treatment. A: Median duration of response (DOR) using modified Response Evaluation Criteria in Solid Tumors; B: Median DOR using RECIST v1.1; C: Median progression-free survival; D: Median overall survival.

Citation: Lin ZP, Hu XL, Chen D, Huang DB, Zou XG, Zhong H, Xu SX, Chen Y, Li XQ, Zhang J. Efficacy and safety of targeted therapy plus immunotherapy combined with hepatic artery infusion chemotherapy (FOLFOX) for unresectable hepatocarcinoma. World J Gastroenterol 2024; 30(17): 2321-2331
URL: https://www.wjgnet.com/1007-9327/full/v30/i17/2321.htm
DOI: https://dx.doi.org/10.3748/wjg.v30.i17.2321